Advertisement
Canada markets close in 48 minutes

  • S&P/TSX

    22,207.37
    -83.25 (-0.37%)
     

  • S&P 500

    5,184.57
    -3.13 (-0.06%)
     

  • DOW

    39,028.15
    +143.89 (+0.37%)
     

  • CAD/USD

    0.7283
    -0.0003 (-0.05%)
     

  • CRUDE OIL

    79.11
    +0.73 (+0.93%)
     

  • Bitcoin CAD

    85,771.96
    -1,013.17 (-1.17%)
     

  • CMC Crypto 200

    1,326.69
    +32.02 (+2.47%)
     

  • GOLD FUTURES

    2,320.20
    -4.00 (-0.17%)
     

  • RUSSELL 2000

    2,052.27
    -12.37 (-0.60%)
     

  • 10-Yr Bond

    4.4940
    +0.0310 (+0.69%)
     

  • NASDAQ

    16,284.82
    -47.74 (-0.29%)
     

  • VOLATILITY

    13.06
    -0.17 (-1.28%)
     

  • FTSE

    8,354.05
    +40.38 (+0.49%)
     

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • CAD/EUR

    0.6775
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

TECH DRAGS STOCKS LOWER AS RALLY HITS PAUSE

Fed's Collins warns interest rates will likely stay higher for longer

Market Potential for Cannabis-Infused Beverages Unleashed as DEA Removes CBD as Schedule 1 Drug

Baystreet.ca
Updated

The increasingly popular cannabis/hemp derivative cannabidiol (CBD) recently received its most important seal of approval, opening up the market to a potential wave of new CBD-infused products. Effective September 28, 2018, the US Drug Enforcement Administration (DEA), CBD has been downgraded from a Schedule I drug to Schedule V, allowing for FDA-approved drugs to contain the cannabinoid. According to industry experts at the Brightfield Group, CBD is growing faster than cannabis in the ... Click here to view full article